ID   DCR1C_HUMAN             Reviewed;         692 AA.
AC   Q96SD1; D3DRT6; Q1HCL2; Q5JSR4; Q5JSR5; Q5JSR7; Q5JSR8; Q5JSR9;
AC   Q5JSS0; Q5JSS7; Q6PK14; Q8N101; Q8N132; Q8TBW9; Q9BVW9; Q9HAM4;
DT   19-JUL-2005, integrated into UniProtKB/Swiss-Prot.
DT   19-JUL-2005, sequence version 2.
DT   07-NOV-2018, entry version 134.
DE   RecName: Full=Protein artemis;
DE            EC=3.1.-.-;
DE   AltName: Full=DNA cross-link repair 1C protein;
DE   AltName: Full=Protein A-SCID;
DE   AltName: Full=SNM1 homolog C;
DE            Short=hSNM1C;
DE   AltName: Full=SNM1-like protein;
GN   Name=DCLRE1C; Synonyms=ARTEMIS, ASCID, SCIDA, SNM1C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AND INVOLVEMENT IN RSSCID.
RX   PubMed=11336668; DOI=10.1016/S0092-8674(01)00309-9;
RA   Moshous D., Callebaut I., de Chasseval R., Corneo B.,
RA   Cavazzana-Calvo M., le Deist F., Tezcan I., Sanal O., Bertrand Y.,
RA   Philippe N., Fischer A., de Villartay J.-P.;
RT   "Artemis, a novel DNA double-strand break repair/V(D)J recombination
RT   protein, is mutated in human severe combined immune deficiency.";
RL   Cell 105:177-186(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3), FUNCTION, SUBCELLULAR
RP   LOCATION, AND INVOLVEMENT IN SCIDA.
RX   PubMed=12055248; DOI=10.4049/jimmunol.168.12.6323;
RA   Li L., Moshous D., Zhou Y., Wang J., Xie G., Salido E., Hu D.,
RA   de Villartay J.-P., Cowan M.J.;
RT   "A founder mutation in Artemis, an SNM1-like protein, causes SCID in
RT   Athabascan-speaking native Americans.";
RL   J. Immunol. 168:6323-6329(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT
RP   ARG-171.
RC   TISSUE=Embryo;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-140; ARG-153;
RP   ARG-171; ARG-243; CYS-320 AND MET-329.
RG   NIEHS SNPs program;
RL   Submitted (APR-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 401-692 (ISOFORMS 1/2/3), AND VARIANT
RP   ARG-243.
RC   TISSUE=Cervix carcinoma, Lung carcinoma, and Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, INTERACTION WITH PRKDC, PHOSPHORYLATION BY PRKDC, AND
RP   MUTAGENESIS OF ASP-165.
RX   PubMed=11955432; DOI=10.1016/S0092-8674(02)00671-2;
RA   Ma Y., Pannicke U., Schwarz K., Lieber M.R.;
RT   "Hairpin opening and overhang processing by an Artemis/DNA-dependent
RT   protein kinase complex in nonhomologous end joining and V(D)J
RT   recombination.";
RL   Cell 108:781-794(2002).
RN   [9]
RP   DNA REPAIR METALLO-BETA-LACTAMASE FAMILY.
RX   PubMed=12177301; DOI=10.1093/nar/gkf470;
RA   Callebaut I., Moshous D., Mornon J.-P., de Villartay J.-P.;
RT   "Metallo-beta-lactamase fold within nucleic acids processing enzymes:
RT   the beta-CASP family.";
RL   Nucleic Acids Res. 30:3592-3601(2002).
RN   [10]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF ASP-17; HIS-33; HIS-35;
RP   ASP-37; HIS-38; HIS-115; ASP-136; ASP-165 AND HIS-319, AND
RP   PHOSPHORYLATION BY PRKDC.
RX   PubMed=15071507; DOI=10.1038/sj.emboj.7600206;
RA   Pannicke U., Ma Y., Hopfner K.-P., Niewolik D., Lieber M.R.,
RA   Schwarz K.;
RT   "Functional and biochemical dissection of the structure-specific
RT   nuclease ARTEMIS.";
RL   EMBO J. 23:1987-1997(2004).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF SER-516; SER-534; SER-538; SER-548; SER-553;
RP   SER-561 AND SER-562, PHOSPHORYLATION BY ATM, AND PHOSPHORYLATION AT
RP   SER-645.
RX   PubMed=15468306; DOI=10.1002/eji.200425455;
RA   Poinsignon C., de Chasseval R., Soubeyrand S., Moshous D., Fischer A.,
RA   Hache R.J.G., de Villartay J.-P.;
RT   "Phosphorylation of Artemis following irradiation-induced DNA
RT   damage.";
RL   Eur. J. Immunol. 34:3146-3155(2004).
RN   [12]
RP   FUNCTION, INTERACTION WITH PRKDC, AND MUTAGENESIS OF ASP-17; HIS-33;
RP   HIS-35; ASP-37; HIS-38; HIS-115; ASP-136; ASP-165 AND HIS-319.
RX   PubMed=14744996; DOI=10.1084/jem.20031142;
RA   Poinsignon C., Moshous D., Callebaut I., de Chasseval R., Villey I.,
RA   de Villartay J.-P.;
RT   "The metallo-beta-lactamase/beta-CASP domain of Artemis constitutes
RT   the catalytic core for V(D)J recombination.";
RL   J. Exp. Med. 199:315-321(2004).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH PRKDC.
RX   PubMed=15574326; DOI=10.1016/j.molcel.2004.11.017;
RA   Ma Y., Lu H., Tippin B., Goodman M.F., Shimazaki N., Koiwai O.,
RA   Hsieh C.-L., Schwarz K., Lieber M.R.;
RT   "A biochemically defined system for mammalian nonhomologous DNA end
RT   joining.";
RL   Mol. Cell 16:701-713(2004).
RN   [14]
RP   FUNCTION, INTERACTION WITH TP53BP1, MUTAGENESIS OF ASP-37, AND
RP   PHOSPHORYLATION BY ATM.
RX   PubMed=15574327; DOI=10.1016/j.molcel.2004.10.029;
RA   Riballo E., Kuehne M., Rief N., Doherty A., Smith G.C.M., Recio M.-J.,
RA   Reis C., Dahm K., Fricke A., Krempler A., Parker A.R., Jackson S.P.,
RA   Gennery A., Jeggo P.A., Loebrich M.;
RT   "A pathway of double-strand break rejoining dependent upon ATM,
RT   Artemis, and proteins locating to gamma-H2AX foci.";
RL   Mol. Cell 16:715-724(2004).
RN   [15]
RP   FUNCTION, INTERACTION WITH ATM; BRCA1; THE MRN COMPLEX AND PRKDC, AND
RP   PHOSPHORYLATION BY ATM; ATR AND PRKDC.
RX   PubMed=15456891; DOI=10.1128/MCB.24.20.9207-9220.2004;
RA   Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D.,
RA   Legerski R.J.;
RT   "Artemis is a phosphorylation target of ATM and ATR and is involved in
RT   the G2/M DNA damage checkpoint response.";
RL   Mol. Cell. Biol. 24:9207-9220(2004).
RN   [16]
RP   INTERACTION WITH THE MRN COMPLEX, PHOSPHORYLATION BY ATM, AND
RP   PHOSPHORYLATION AT SER-645.
RX   PubMed=15723659; DOI=10.1111/j.1349-7006.2005.00019.x;
RA   Chen L., Morio T., Minegishi Y., Nakada S., Nagasawa M., Komatsu K.,
RA   Chessa L., Villa A., Lecis D., Delia D., Mizutani S.;
RT   "Ataxia-telangiectasia-mutated dependent phosphorylation of Artemis in
RT   response to DNA damage.";
RL   Cancer Sci. 96:134-141(2005).
RN   [17]
RP   FUNCTION, PHOSPHORYLATION BY PRKDC, AND PHOSPHORYLATION IN RESPONSE TO
RP   DNA DAMAGE.
RX   PubMed=15811628; DOI=10.1016/j.dnarep.2005.02.001;
RA   Wang J., Pluth J.M., Cooper P.K., Cowan M.J., Chen D.J., Yannone S.M.;
RT   "Artemis deficiency confers a DNA double-strand break repair defect
RT   and Artemis phosphorylation status is altered by DNA damage and cell
RT   cycle progression.";
RL   DNA Repair 4:556-570(2005).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH PRKDC.
RX   PubMed=15936993; DOI=10.1016/j.dnarep.2005.04.013;
RA   Ma Y., Schwarz K., Lieber M.R.;
RT   "The Artemis:DNA-PKcs endonuclease cleaves DNA loops, flaps, and
RT   gaps.";
RL   DNA Repair 4:845-851(2005).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   VARIANTS RSSCID VAL-118 AND GLU-135.
RX   PubMed=12406895; DOI=10.1182/blood-2002-01-0187;
RA   Noordzij J.G., Verkaik N.S., van der Burg M., van Veelen L.R.,
RA   de Bruin-Versteeg S., Wiegant W., Vossen J.M.J.J., Weemaes C.M.R.,
RA   de Groot R., Zdzienicka M.Z., van Gent D.C., van Dongen J.J.M.;
RT   "Radiosensitive SCID patients with Artemis gene mutations show a
RT   complete B-cell differentiation arrest at the pre-B-cell receptor
RT   checkpoint in bone marrow.";
RL   Blood 101:1446-1452(2003).
RN   [22]
RP   INVOLVEMENT IN RSSCID.
RX   PubMed=12921762; DOI=10.1016/S1521-6616(03)00095-0;
RA   Kobayashi N., Agematsu K., Nagumo H., Yasui K., Katsuyama Y.,
RA   Yoshizawa K., Ota M., Yachie A., Komiyama A.;
RT   "Expansion of clonotype-restricted HLA-identical maternal CD4+ T cells
RT   in a patient with severe combined immunodeficiency and a homozygous
RT   mutation in the Artemis gene.";
RL   Clin. Immunol. 108:159-166(2003).
RN   [23]
RP   INVOLVEMENT IN RSSCID.
RX   PubMed=12592555; DOI=10.1007/s00439-002-0897-x;
RA   Kobayashi N., Agematsu K., Sugita K., Sako M., Nonoyama S., Yachie A.,
RA   Kumaki S., Tsuchiya S., Ochs H.D., Sugita K., Fukushima Y.,
RA   Komiyama A.;
RT   "Novel Artemis gene mutations of radiosensitive severe combined
RT   immunodeficiency in Japanese families.";
RL   Hum. Genet. 112:348-352(2003).
RN   [24]
RP   INVOLVEMENT IN RSSCID.
RX   PubMed=12569164; DOI=10.1172/JCI16774;
RA   Moshous D., Pannetier C., de Chasseval R., le Deist F.,
RA   Cavazzana-Calvo M., Romana S., Macintyre E., Canioni D., Brousse N.,
RA   Fischer A., Casanova J.-L., de Villartay J.-P.;
RT   "Partial T and B lymphocyte immunodeficiency and predisposition to
RT   lymphoma in patients with hypomorphic mutations in Artemis.";
RL   J. Clin. Invest. 111:381-387(2003).
RN   [25]
RP   VARIANT OMENN SYNDROME ASP-35.
RX   PubMed=15731174; DOI=10.1182/blood-2004-12-4861;
RA   Ege M., Ma Y., Manfras B., Kalwak K., Lu H., Lieber M.R., Schwarz K.,
RA   Pannicke U.;
RT   "Omenn syndrome due to ARTEMIS mutations.";
RL   Blood 105:4179-4186(2005).
CC   -!- FUNCTION: Required for V(D)J recombination, the process by which
CC       exons encoding the antigen-binding domains of immunoglobulins and
CC       T-cell receptor proteins are assembled from individual V, (D), and
CC       J gene segments. V(D)J recombination is initiated by the lymphoid
CC       specific RAG endonuclease complex, which generates site specific
CC       DNA double strand breaks (DSBs). These DSBs present two types of
CC       DNA end structures: hairpin sealed coding ends and phosphorylated
CC       blunt signal ends. These ends are independently repaired by the
CC       non homologous end joining (NHEJ) pathway to form coding and
CC       signal joints respectively. This protein exhibits single-strand
CC       specific 5'-3' exonuclease activity in isolation and acquires
CC       endonucleolytic activity on 5' and 3' hairpins and overhangs when
CC       in a complex with PRKDC. The latter activity is required
CC       specifically for the resolution of closed hairpins prior to the
CC       formation of the coding joint. May also be required for the repair
CC       of complex DSBs induced by ionizing radiation, which require
CC       substantial end-processing prior to religation by NHEJ.
CC       {ECO:0000269|PubMed:11336668, ECO:0000269|PubMed:11955432,
CC       ECO:0000269|PubMed:12055248, ECO:0000269|PubMed:14744996,
CC       ECO:0000269|PubMed:15071507, ECO:0000269|PubMed:15456891,
CC       ECO:0000269|PubMed:15468306, ECO:0000269|PubMed:15574326,
CC       ECO:0000269|PubMed:15574327, ECO:0000269|PubMed:15811628,
CC       ECO:0000269|PubMed:15936993}.
CC   -!- SUBUNIT: Interacts with ATM, BRCA1, PRKDC and TP53BP1. Also
CC       exhibits ATM- and phosphorylation-dependent interaction with the
CC       MRN complex, composed of MRE11, RAD50, and NBN.
CC       {ECO:0000269|PubMed:11955432, ECO:0000269|PubMed:14744996,
CC       ECO:0000269|PubMed:15456891, ECO:0000269|PubMed:15574326,
CC       ECO:0000269|PubMed:15574327, ECO:0000269|PubMed:15723659,
CC       ECO:0000269|PubMed:15936993}.
CC   -!- INTERACTION:
CC       P49917:LIG4; NbExp=16; IntAct=EBI-11694104, EBI-847896;
CC       P78527:PRKDC; NbExp=4; IntAct=EBI-11694104, EBI-352053;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12055248,
CC       ECO:0000269|PubMed:15071507}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q96SD1-1; Sequence=Displayed;
CC       Name=2; Synonyms=SCIDA;
CC         IsoId=Q96SD1-2; Sequence=VSP_014888;
CC       Name=3;
CC         IsoId=Q96SD1-3; Sequence=VSP_014889, VSP_014890;
CC       Name=4;
CC         IsoId=Q96SD1-4; Sequence=VSP_014891, VSP_014892;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       the kidney, lung, pancreas and placenta (at the mRNA level).
CC       Expression is not increased in thymus or bone marrow, sites of
CC       V(D)J recombination. {ECO:0000269|PubMed:11336668}.
CC   -!- PTM: Phosphorylation on undefined residues by PRKDC may stimulate
CC       endonucleolytic activity on 5' and 3' hairpins and overhangs.
CC       PRKDC must remain present, even after phosphorylation, for
CC       efficient hairpin opening. Also phosphorylated by ATM in response
CC       to ionizing radiation (IR) and by ATR in response to ultraviolet
CC       (UV) radiation. {ECO:0000269|PubMed:11955432,
CC       ECO:0000269|PubMed:15071507, ECO:0000269|PubMed:15456891,
CC       ECO:0000269|PubMed:15468306, ECO:0000269|PubMed:15574327,
CC       ECO:0000269|PubMed:15723659, ECO:0000269|PubMed:15811628}.
CC   -!- DISEASE: Severe combined immunodeficiency autosomal recessive T-
CC       cell-negative/B-cell-negative/NK-cell-positive with sensitivity to
CC       ionizing radiation (RSSCID) [MIM:602450]: A form of severe
CC       combined immunodeficiency, a genetically and clinically
CC       heterogeneous group of rare congenital disorders characterized by
CC       impairment of both humoral and cell-mediated immunity, leukopenia,
CC       and low or absent antibody levels. Patients present in infancy
CC       with recurrent, persistent infections by opportunistic organisms.
CC       The common characteristic of all types of SCID is absence of T-
CC       cell-mediated cellular immunity due to a defect in T-cell
CC       development. Individuals affected by RS-SCID show defects in the
CC       DNA repair machinery necessary for coding joint formation and the
CC       completion of V(D)J recombination. A subset of cells from such
CC       patients show increased radiosensitivity.
CC       {ECO:0000269|PubMed:11336668, ECO:0000269|PubMed:12406895,
CC       ECO:0000269|PubMed:12569164, ECO:0000269|PubMed:12592555,
CC       ECO:0000269|PubMed:12921762}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Severe combined immunodeficiency Athabaskan type (SCIDA)
CC       [MIM:602450]: A variety of SCID with sensitivity to ionizing
CC       radiation. A founder mutation has been detected in Athabascan-
CC       speaking native Americans, being inherited as an autosomal
CC       recessive trait. Affected individuals exhibit clinical symptoms
CC       and defects in DNA repair comparable to those seen in RS-SCID.
CC       {ECO:0000269|PubMed:12055248}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Omenn syndrome (OS) [MIM:603554]: Severe immunodeficiency
CC       characterized by the presence of activated, anergic, oligoclonal
CC       T-cells, hypereosinophilia, and high IgE levels.
CC       {ECO:0000269|PubMed:15731174}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the DNA repair metallo-beta-lactamase
CC       (DRMBL) family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=DCLRE1Cbase; Note=DCLRE1C mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/DCLRE1Cbase/";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/dclre1c/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ296101; CAC37570.1; -; mRNA.
DR   EMBL; AF395747; AAM53255.1; -; mRNA.
DR   EMBL; AF395748; AAM53256.1; -; mRNA.
DR   EMBL; AF395749; AAM53257.1; -; mRNA.
DR   EMBL; AF395750; AAM53258.1; -; mRNA.
DR   EMBL; AF395751; AAM53259.1; -; mRNA.
DR   EMBL; AF395752; AAM53260.1; -; mRNA.
DR   EMBL; AK021422; BAB13820.1; -; mRNA.
DR   EMBL; DQ504427; ABF47101.1; -; Genomic_DNA.
DR   EMBL; AC069544; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL360083; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471072; EAW86248.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86250.1; -; Genomic_DNA.
DR   EMBL; CH471072; EAW86251.1; -; Genomic_DNA.
DR   EMBL; BC000863; AAH00863.1; -; mRNA.
DR   EMBL; BC009185; AAH09185.1; -; mRNA.
DR   EMBL; BC022254; AAH22254.1; -; mRNA.
DR   CCDS; CCDS31149.1; -. [Q96SD1-1]
DR   CCDS; CCDS31150.1; -. [Q96SD1-2]
DR   CCDS; CCDS7105.1; -. [Q96SD1-3]
DR   RefSeq; NP_001029027.1; NM_001033855.2. [Q96SD1-1]
DR   RefSeq; NP_001029029.1; NM_001033857.2. [Q96SD1-2]
DR   RefSeq; NP_001029030.1; NM_001033858.2. [Q96SD1-2]
DR   RefSeq; NP_001276005.1; NM_001289076.1. [Q96SD1-3]
DR   RefSeq; NP_001276006.1; NM_001289077.1. [Q96SD1-2]
DR   RefSeq; NP_001276007.1; NM_001289078.1. [Q96SD1-3]
DR   RefSeq; NP_001276008.1; NM_001289079.1. [Q96SD1-2]
DR   RefSeq; NP_071932.2; NM_022487.3. [Q96SD1-3]
DR   RefSeq; XP_006717554.1; XM_006717491.3. [Q96SD1-3]
DR   RefSeq; XP_011517918.1; XM_011519616.1. [Q96SD1-3]
DR   RefSeq; XP_011517919.1; XM_011519617.1. [Q96SD1-3]
DR   RefSeq; XP_011517921.1; XM_011519619.1. [Q96SD1-2]
DR   RefSeq; XP_016872046.1; XM_017016557.1. [Q96SD1-3]
DR   RefSeq; XP_016872047.1; XM_017016558.1. [Q96SD1-2].
DR   PDB; 3W1B; X-ray; 2.40 A; B=485-495.
DR   PDB; 3W1G; X-ray; 2.55 A; B=485-495.
DR   PDB; 4HTP; X-ray; 2.25 A; C/E=485-495.
DR   PDBsum; 3W1B; -.
DR   PDBsum; 3W1G; -.
DR   PDBsum; 4HTP; -.
DR   SMR; Q96SD1; -.
DR   BioGrid; 122170; 36.
DR   CORUM; Q96SD1; -.
DR   IntAct; Q96SD1; 3.
DR   STRING; 9606.ENSP00000367527; -.
DR   BindingDB; Q96SD1; -.
DR   iPTMnet; Q96SD1; -.
DR   PhosphoSitePlus; Q96SD1; -.
DR   BioMuta; DCLRE1C; -.
DR   DMDM; 71153325; -.
DR   EPD; Q96SD1; -.
DR   MaxQB; Q96SD1; -.
DR   PaxDb; Q96SD1; -.
DR   PeptideAtlas; Q96SD1; -.
DR   PRIDE; Q96SD1; -.
DR   ProteomicsDB; 78103; -.
DR   ProteomicsDB; 78104; -. [Q96SD1-2]
DR   ProteomicsDB; 78105; -. [Q96SD1-3]
DR   ProteomicsDB; 78106; -. [Q96SD1-4]
DR   Ensembl; ENST00000357717; ENSP00000350349; ENSG00000152457. [Q96SD1-3]
DR   Ensembl; ENST00000378246; ENSP00000367492; ENSG00000152457. [Q96SD1-3]
DR   Ensembl; ENST00000378249; ENSP00000367496; ENSG00000152457. [Q96SD1-3]
DR   Ensembl; ENST00000378254; ENSP00000367502; ENSG00000152457. [Q96SD1-2]
DR   Ensembl; ENST00000378255; ENSP00000367503; ENSG00000152457. [Q96SD1-2]
DR   Ensembl; ENST00000378258; ENSP00000367506; ENSG00000152457. [Q96SD1-2]
DR   Ensembl; ENST00000378278; ENSP00000367527; ENSG00000152457. [Q96SD1-1]
DR   Ensembl; ENST00000378289; ENSP00000367538; ENSG00000152457. [Q96SD1-4]
DR   Ensembl; ENST00000396817; ENSP00000380030; ENSG00000152457. [Q96SD1-2]
DR   GeneID; 64421; -.
DR   KEGG; hsa:64421; -.
DR   UCSC; uc001inl.5; human. [Q96SD1-1]
DR   CTD; 64421; -.
DR   DisGeNET; 64421; -.
DR   EuPathDB; HostDB:ENSG00000152457.17; -.
DR   GeneCards; DCLRE1C; -.
DR   HGNC; HGNC:17642; DCLRE1C.
DR   HPA; HPA069295; -.
DR   MalaCards; DCLRE1C; -.
DR   MIM; 602450; phenotype.
DR   MIM; 603554; phenotype.
DR   MIM; 605988; gene.
DR   neXtProt; NX_Q96SD1; -.
DR   OpenTargets; ENSG00000152457; -.
DR   Orphanet; 39041; Omenn syndrome.
DR   Orphanet; 275; Severe combined immunodeficiency due to DCLRE1C deficiency.
DR   PharmGKB; PA27176; -.
DR   eggNOG; KOG1361; Eukaryota.
DR   eggNOG; COG1236; LUCA.
DR   GeneTree; ENSGT00530000063183; -.
DR   InParanoid; Q96SD1; -.
DR   KO; K10887; -.
DR   OMA; CYSTHAS; -.
DR   OrthoDB; EOG091G0TAU; -.
DR   PhylomeDB; Q96SD1; -.
DR   TreeFam; TF329572; -.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   SIGNOR; Q96SD1; -.
DR   ChiTaRS; DCLRE1C; human.
DR   GenomeRNAi; 64421; -.
DR   PRO; PR:Q96SD1; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000152457; Expressed in 235 organ(s), highest expression level in buccal mucosa cell.
DR   ExpressionAtlas; Q96SD1; baseline and differential.
DR   Genevisible; Q96SD1; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:HPA.
DR   GO; GO:0070419; C:nonhomologous end joining complex; IDA:UniProtKB.
DR   GO; GO:0000784; C:nuclear chromosome, telomeric region; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0035312; F:5'-3' exodeoxyribonuclease activity; IBA:GO_Central.
DR   GO; GO:0008409; F:5'-3' exonuclease activity; IDA:MGI.
DR   GO; GO:0003684; F:damaged DNA binding; IBA:GO_Central.
DR   GO; GO:0004519; F:endonuclease activity; TAS:Reactome.
DR   GO; GO:0000014; F:single-stranded DNA endodeoxyribonuclease activity; IDA:MGI.
DR   GO; GO:0002250; P:adaptive immune response; IEA:UniProtKB-KW.
DR   GO; GO:0030183; P:B cell differentiation; IEA:Ensembl.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; IBA:GO_Central.
DR   GO; GO:0036297; P:interstrand cross-link repair; IBA:GO_Central.
DR   GO; GO:0031848; P:protection from non-homologous end joining at telomere; IBA:GO_Central.
DR   GO; GO:0010212; P:response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0033151; P:V(D)J recombination; IEA:Ensembl.
DR   Gene3D; 3.60.15.10; -; 1.
DR   InterPro; IPR011084; DRMBL.
DR   InterPro; IPR001279; Metallo-B-lactamas.
DR   InterPro; IPR036866; RibonucZ/Hydroxyglut_hydro.
DR   Pfam; PF07522; DRMBL; 1.
DR   Pfam; PF12706; Lactamase_B_2; 1.
DR   SUPFAM; SSF56281; SSF56281; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Adaptive immunity; Alternative splicing;
KW   Complete proteome; Disease mutation; DNA damage; DNA recombination;
KW   DNA repair; Endonuclease; Exonuclease; Hydrolase; Immunity; Magnesium;
KW   Nuclease; Nucleus; Phosphoprotein; Polymorphism; Reference proteome;
KW   SCID.
FT   CHAIN         1    692       Protein artemis.
FT                                /FTId=PRO_0000209122.
FT   MOD_RES     380    380       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q8K4J0}.
FT   MOD_RES     385    385       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8K4J0}.
FT   MOD_RES     645    645       Phosphoserine; by ATM.
FT                                {ECO:0000269|PubMed:15468306,
FT                                ECO:0000269|PubMed:15723659}.
FT   VAR_SEQ       1    120       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12055248}.
FT                                /FTId=VSP_014888.
FT   VAR_SEQ       1    115       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:12055248,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014889.
FT   VAR_SEQ     116    121       CPGSVM -> MKHQER (in isoform 3).
FT                                {ECO:0000303|PubMed:12055248,
FT                                ECO:0000303|PubMed:14702039,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014890.
FT   VAR_SEQ     386    434       EEEDDYLFDDPLPIPLRHKVPYPETFHPEVFSMTAVSEKQP
FT                                EKLRQTPG -> GSHSVTQARMRWCHHDSLYPLTPGIKRSS
FT                                CLSLLTSWITGAYRHAQLMI (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014891.
FT   VAR_SEQ     435    692       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_014892.
FT   VARIANT      35     35       H -> D (in Omenn syndrome;
FT                                dbSNP:rs121908159).
FT                                {ECO:0000269|PubMed:15731174}.
FT                                /FTId=VAR_023077.
FT   VARIANT     118    118       G -> V (in RSSCID).
FT                                {ECO:0000269|PubMed:12406895}.
FT                                /FTId=VAR_023078.
FT   VARIANT     135    135       G -> E (in RSSCID).
FT                                {ECO:0000269|PubMed:12406895}.
FT                                /FTId=VAR_023079.
FT   VARIANT     140    140       A -> V (in dbSNP:rs41297016).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_060689.
FT   VARIANT     153    153       G -> R (in dbSNP:rs41297018).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_060690.
FT   VARIANT     171    171       P -> R (in dbSNP:rs35441642).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_048892.
FT   VARIANT     243    243       H -> R (in dbSNP:rs12768894).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_048893.
FT   VARIANT     320    320       S -> C (in dbSNP:rs41298896).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_048894.
FT   VARIANT     329    329       L -> M (in dbSNP:rs41299658).
FT                                {ECO:0000269|Ref.4}.
FT                                /FTId=VAR_060691.
FT   MUTAGEN      17     17       D->N,A: Abolishes PRKDC-dependent
FT                                endonuclease activity and V(D)J
FT                                recombination.
FT                                {ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507}.
FT   MUTAGEN      33     33       H->A: Abolishes PRKDC-dependent
FT                                endonuclease activity and V(D)J
FT                                recombination.
FT                                {ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507}.
FT   MUTAGEN      35     35       H->A: Abolishes PRKDC-dependent
FT                                endonuclease activity and V(D)J
FT                                recombination.
FT                                {ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507}.
FT   MUTAGEN      37     37       D->N,A: Abolishes PRKDC-dependent
FT                                endonuclease activity and V(D)J
FT                                recombination.
FT                                {ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507,
FT                                ECO:0000269|PubMed:15574327}.
FT   MUTAGEN      38     38       H->A: Reduces PRKDC-dependent
FT                                endonuclease activity, although V(D)J
FT                                recombination is largely normal.
FT                                {ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507}.
FT   MUTAGEN     115    115       H->A: Abolishes PRKDC-dependent
FT                                endonuclease activity and V(D)J
FT                                recombination.
FT                                {ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507}.
FT   MUTAGEN     136    136       D->N,A: Abolishes PRKDC-dependent
FT                                endonuclease activity and V(D)J
FT                                recombination.
FT                                {ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507}.
FT   MUTAGEN     165    165       D->N,A: Abolishes PRKDC-dependent
FT                                endonuclease activity and V(D)J
FT                                recombination.
FT                                {ECO:0000269|PubMed:11955432,
FT                                ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507}.
FT   MUTAGEN     319    319       H->A: Abolishes PRKDC-dependent
FT                                endonuclease activity and V(D)J
FT                                recombination.
FT                                {ECO:0000269|PubMed:14744996,
FT                                ECO:0000269|PubMed:15071507}.
FT   MUTAGEN     516    516       S->A: Reduced IR induced phosphorylation;
FT                                when associated with A-534; A-538; A-548;
FT                                A-553; A-561 and A-562.
FT                                {ECO:0000269|PubMed:15468306}.
FT   MUTAGEN     534    534       S->A: Reduced IR induced phosphorylation;
FT                                when associated with A-516; A-538; A-548;
FT                                A-553; A-561 and A-562.
FT                                {ECO:0000269|PubMed:15468306}.
FT   MUTAGEN     538    538       S->A: Reduced IR induced phosphorylation;
FT                                when associated with A-516; A-534; A-548;
FT                                A-553; A-561 and A-562.
FT                                {ECO:0000269|PubMed:15468306}.
FT   MUTAGEN     548    548       S->A: Reduced IR induced phosphorylation;
FT                                when associated with A-516; A-534; A-538;
FT                                A-553; A-561 and A-562.
FT                                {ECO:0000269|PubMed:15468306}.
FT   MUTAGEN     553    553       S->A: Reduced IR induced phosphorylation;
FT                                when associated with A-516; A-534; A-538;
FT                                A-548; A-561 and A-562.
FT                                {ECO:0000269|PubMed:15468306}.
FT   MUTAGEN     561    561       S->A: Reduced IR induced phosphorylation;
FT                                when associated with A-516; A-534; A-538;
FT                                A-548; A-553 and A-562.
FT                                {ECO:0000269|PubMed:15468306}.
FT   MUTAGEN     562    562       S->A: Reduced IR induced phosphorylation;
FT                                when associated with A-516; A-534; A-538;
FT                                A-548; A-553 and A-561.
FT                                {ECO:0000269|PubMed:15468306}.
FT   CONFLICT    560    560       L -> V (in Ref. 1; CAC37570 and 2;
FT                                AAM53255/AAM53256/AAM53257/AAM53258/
FT                                AAM53259/AAM53260). {ECO:0000305}.
FT   HELIX       489    491       {ECO:0000244|PDB:4HTP}.
SQ   SEQUENCE   692 AA;  78436 MW;  24B857F5B473637B CRC64;
     MSSFEGQMAE YPTISIDRFD RENLRARAYF LSHCHKDHMK GLRAPTLKRR LECSLKVYLY
     CSPVTKELLL TSPKYRFWKK RIISIEIETP TQISLVDEAS GEKEEIVVTL LPAGHCPGSV
     MFLFQGNNGT VLYTGDFRLA QGEAARMELL HSGGRVKDIQ SVYLDTTFCD PRFYQIPSRE
     ECLSGVLELV RSWITRSPYH VVWLNCKAAY GYEYLFTNLS EELGVQVHVN KLDMFRNMPE
     ILHHLTTDRN TQIHACRHPK AEEYFQWSKL PCGITSRNRI PLHIISIKPS TMWFGERSRK
     TNVIVRTGES SYRACFSFHS SYSEIKDFLS YLCPVNAYPN VIPVGTTMDK VVEILKPLCR
     SSQSTEPKYK PLGKLKRART VHRDSEEEDD YLFDDPLPIP LRHKVPYPET FHPEVFSMTA
     VSEKQPEKLR QTPGCCRAEC MQSSRFTNFV DCEESNSESE EEVGIPASLQ GDLGSVLHLQ
     KADGDVPQWE VFFKRNDEIT DESLENFPSS TVAGGSQSPK LFSDSDGEST HISSQNSSQS
     THITEQGSQG WDSQSDTVLL SSQERNSGDI TSLDKADYRP TIKENIPASL MEQNVICPKD
     TYSDLKSRDK DVTIVPSTGE PTTLSSETHI PEEKSLLNLS TNADSQSSSD FEVPSTPEAE
     LPKREHLQYL YEKLATGESI AVKKRKCSLL DT
//